Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Diagnosis and Management of Multiple Sclerosis in Children



Najafi MR1, 3 ; Najafi MA2, 3 ; Nasr Z2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan University of Medical Sciences, Faculty of Medicine, Isfahan, Iran
  3. 3. Isfahan Neurosciences Research Centre (INRC), Isfahan University of Medical Sciences, Isfahan, Iran

Source: Iranian Journal of Child Neurology Published:2016

Abstract

Growing evidence indicates the safety and well toleration of treatment by Disease-modifying in children suffering multiple sclerosis (MS). The treatment is not straight forward in a great number of patients, thus patients with pediatric MS must be managed by experienced specialized centers. Common treatments of multiple sclerosis for adults are first-line therapies. These therapies (firstline) are safe for children. Failure in treatment that leads to therapy alteration is almost prevalent in pediatric MS. Toleration against current second-line therapies has been shown in multiple sclerosis children. Oral agents have not been assessed in children MS patients. Although clinical trials in children are insufficient, immunomodulating managed children, experience a side effect similar to the adult MS patients. However, further prospective clinical studies, with large sample size and long follow-up are needed to distinguish the benefits and probable side effects of pediatric MS therapies. © 2016, Iranian Child Neurology Society. All rights reserved.
Related Docs
View other Related Docs
1. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study, Neurology (2024)
2. Anti-Cd20 Therapies for Pediatric-Onset Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2024)
3. Comparing the Efficacy of Monthly Cyclophosphamide As Monotherapy Versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis, Journal of Isfahan Medical School (2017)
4. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
5. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
6. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
7. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
8. Prognostic Indicators in Pediatric Clinically Isolated Syndrome, Annals of Neurology (2017)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (68)
Masoud Etemadifar (62)
Other Related Docs
9. Early-Onset Multiple Sclerosis in Isfahan, Iran: Report of the Demographic and Clinical Features of 221 Patients, Journal of Child Neurology (2016)
10. Safety and Efficacy of Mitoxantrone in Pediatric Patients With Aggressive Multiple Sclerosis, European Journal of Paediatric Neurology (2014)
11. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)
12. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
13. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
14. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Neurology (2022)
15. Pediatric Multiple Sclerosis With Primary Progressive Course-Report of a Retrospective Cohort Study in Iran, Neuropediatrics (2013)
16. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
17. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
18. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)
19. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
20. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
21. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis, BMC Medical Research Methodology (2022)
22. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
23. Examining the Environmental Risk Factors of Progressive-Onset and Relapsing-Onset Multiple Sclerosis: Recruitment Challenges, Potential Bias, and Statistical Strategies, Journal of Neurology (2024)
24. Combination Therapy With Mitoxantrone and Plasma Exchange in Aggressive Relapsing Remitting Multiple Sclerosis: A Preliminary Clinical Study, Journal of Research in Medical Sciences (2012)
25. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
26. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
27. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
28. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
29. The Frequency of Varicella-Zoster Virus Infection in Patients With Multiple Sclerosis Receiving Fingolimod, Journal of Neuroimmunology (2019)
30. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
31. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
32. Assessment of Mental Health, Knowledge, and Attitude of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Response to 2019 Novel Coronavirus, Neurological Sciences (2021)
33. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis in the United Kingdom, Journal of Medical Economics (2024)
34. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
35. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
36. Bone Loss and Fracture in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
37. Multiple Sclerosis Epidemiology in Asia and Oceania; a Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
38. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
39. Evaluating the Effect of Adding Fish Oil to Fingolimod on Tnf-Α Il1β Il6, and Ifn-Γ in Patients With Relapsing-Remitting Multiple Sclerosis: A Double-Blind Randomized Placebo-Controlled Trial, Clinical Neurology and Neurosurgery (2017)
40. Assessment of Intelligence Quotient in Patients With Neuromyelitis Optica Spectrum Disease and Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
41. Association Between Diffusion Tensor Imaging Measurements and Cognitive Performances in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2025)
42. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
43. Incidence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Treated With Fingolimod: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
44. Prevalence of Trigeminal Neuralgia in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2022)
45. Prenatal and Perinatal Factors Associated With Developing Multiple Sclerosis Later in Life: A Systematic Review and Meta-Analysis, Autoimmunity Reviews (2021)
46. Risk Factors of Severe Covid-19 in People With Multiple Sclerosis : A Systematic Review and Meta-Analysis, Revue Neurologique (2022)
47. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
48. The Effect of Ginger (Zingiber Officinale) Supplementation on Clinical, Biochemical, and Anthropometric Parameters in Patients With Multiple Sclerosis: A Double-Blind Randomized Controlled Trial, Food and Function (2023)
49. Side Effects of Methylprednisolone Pulse Therapy in Treatment of Multiple Sclerosis, Journal of Isfahan Medical School (2012)
50. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies, Neurology: Neuroimmunology and NeuroInflammation (2024)